BMS secures FDA accelerated approval for Zenbexus in multiple myeloma
In combination with ZDd, Zenbexus received the agency’s decision following results from the Phase III EXCALIBER-RRMM trial.
Drug Development
Xanadu and University of Alberta to develop quantum algorithms for cancer
Akeso secures China NMPA authorisation for ivonescimab combo
Remepy secures $36m funding for hybrid drug pipeline expansion
Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat
Alfasigma signs agreement to acquire Nordic Group
BeOne and Revolution Medicines partner for oncology therapies
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
